{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:28:26Z","timestamp":1786681706778,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether discontinuing anti\u2010CD20 therapy in people with relapsing\u2010onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational, multicenter, retrospective cohort study included 2283 patients from the French MS registry aged &gt;\u200950, who had received at least two cycles of anti\u2010CD20 and had experienced no relapses or MRI activity for at least one year prior to inclusion. Patients were classified as discontinuing or continuing therapy and 1:1 matched using a time\u2010dependent propensity score. Outcomes were time to first relapse, inflammatory activity (relapse and\/or MRI activity), confirmed disability accrual, and serious infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1900 patients continuing therapy and 383 discontinuing, 224 in each group were matched (mean age\u2009=\u200957.7\u2009\u00b1\u20095.9\u2009years; mean EDSS\u2009=\u20095.4\u2009\u00b1\u20091.7; median follow\u2010up after matching\u2009=\u200934.8 [21.6\u201350.4] months). There were no significant differences between groups in time to first relapse (HR\u2009=\u20090.6, 95% CI 0.3\u20131.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.2), inflammatory activity (HR\u2009=\u20090.9, 95% CI 0.5\u20131.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.6), confirmed disability accrual (HR\u2009=\u20091.2, 95% CI 0.9\u20131.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.2), and serious infections (HR\u2009=\u20091.0, 95% CI 0.6\u20131.8,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.9).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>This retrospective study found no evidence of differences between stopping and continuing anti\u2010CD20 therapy regarding relapse, inflammatory activity, disability accrual, or serious infections in older patients with long\u2010standing non\u2010active MS over a median 2.9\u2010year follow\u2010up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acn3.70497","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:58:09Z","timestamp":1786679889000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti\u2010\n                    <scp>CD20<\/scp>\n                    Discontinuation Versus Continuation in People Aged Over 50 With Non\u2010Active Multiple Sclerosis"],"prefix":"10.1002","author":[{"given":"Alexia","family":"Moukhine","sequence":"first","affiliation":[{"name":"Department of Neurology University Hospital of Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-2331","authenticated-orcid":false,"given":"Fabien","family":"Rollot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard, Lyon 1  Lyon France"},{"name":"Department of Neurology H\u00f4pital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Scl\u00e9rose en Plaques, Pathologies de la My\u00e9line et Neuro\u2010Inflammation  Bron France"},{"name":"Centre de Recherche en Neurosciences de Lyon, Observatoire Fran\u00e7ais de La Scl\u00e9rose en Plaques, INSERM 1028 and CNRS UMR 5292  Lyon France"},{"name":"Eug\u00e8ne Devic EDMUS Foundation Against Multiple Sclerosis, State\u2010Approved Foundation  Bron France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Casey","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard, Lyon 1  Lyon France"},{"name":"Department of Neurology H\u00f4pital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Scl\u00e9rose en Plaques, Pathologies de la My\u00e9line et Neuro\u2010Inflammation  Bron France"},{"name":"Centre de Recherche en Neurosciences de Lyon, Observatoire Fran\u00e7ais de La Scl\u00e9rose en Plaques, INSERM 1028 and CNRS UMR 5292  Lyon France"},{"name":"Eug\u00e8ne Devic EDMUS Foundation Against Multiple Sclerosis, State\u2010Approved Foundation  Bron France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Investigation Center CIC 1434, INSERM 1434, CHU de Strasbourg  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard, Lyon 1  Lyon France"},{"name":"Department of Neurology H\u00f4pital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Scl\u00e9rose en Plaques, Pathologies de la My\u00e9line et Neuro\u2010Inflammation  Bron France"},{"name":"Centre de Recherche en Neurosciences de Lyon, Observatoire Fran\u00e7ais de La Scl\u00e9rose en Plaques, INSERM 1028 and CNRS UMR 5292  Lyon France"},{"name":"Eug\u00e8ne Devic EDMUS Foundation Against Multiple Sclerosis, State\u2010Approved Foundation  Bron France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mathey","sequence":"additional","affiliation":[{"name":"Department of Neurology Nancy University Hospital  Nancy France"},{"name":"Universit\u00e9 de Lorraine, APEMAC  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Laure","family":"Dubessy","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Neurologie H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re, APHP  Paris France"},{"name":"Centre de Ressources et de Comp\u00e9tences SEP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[{"name":"Department of Neurology CRC\u2010SEP, CHU de Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"De Seze","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Investigation Center CIC 1434, INSERM 1434, CHU de Strasbourg  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Ruet","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital of Bordeaux  Bordeaux France"},{"name":"Neurocentre Magendie Bordeaux University, INSERM U1215  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Labauge","sequence":"additional","affiliation":[{"name":"MS Unit CHU de Montpellier  Montpellier Cedex 5 France"},{"name":"University of Montpellier (MUSE)  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Groupement des H\u00f4pitaux de l'Institut Catholique de Lille H\u00f4pital Saint Vincent de Paul  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Zephir","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lille, Inserm U1172, CRC\u2010SEP de Lille, CHU de Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[{"name":"Department of Neurology Foundation Adolphe de Rothschild Hospital, Universit\u00e9 Paris\u2010Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Defer","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHU de Caen, MS Expert Centre, Avenue de la C\u00f4te\u2010de\u2010Nacre Normandy University  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-2416","authenticated-orcid":false,"given":"Christine","family":"Lebrun\u2010Frenay","sequence":"additional","affiliation":[{"name":"Neurology UR2CA_URRIS, Centre Hospitalier Universitaire Pasteur2, Universit\u00e9 Nice C\u00f4te d'Azur  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Axel","family":"Laplaud","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CIC INSERM 1413, CRC\u2010SEP Pays de la Loire, Service de Neurologie  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Berger","sequence":"additional","affiliation":[{"name":"Service de Neurologie CHU de Besan\u00e7on  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Thouvenot","sequence":"additional","affiliation":[{"name":"CHU Nimes, Service de Neurologie, University of Montpellier  Nimes France"},{"name":"Institut de G\u00e9nomique Fonctionnelle, University of Montpellier, CNRS, INSERM  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, H\u00f4pital de la Timone P\u00f4le de Neurosciences Cliniques, Service de Neurologie  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullatif","family":"Al Khedr","sequence":"additional","affiliation":[{"name":"Department of Neurology CHU d'Amiens  Amiens France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casez","sequence":"additional","affiliation":[{"name":"Department of Neurology, CHU Grenoble Alpes, Neurology MS Clinic Grenoble Grenoble Alpes University Hospital  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Bourre","sequence":"additional","affiliation":[{"name":"T\u2010RAIG, TIMC\u2010IMAG, Grenoble Alpes University  Grenoble France"},{"name":"Department of Neurology CHU de Rouen  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Wahab","sequence":"additional","affiliation":[{"name":"Department of Neurology APHP, H\u00f4pital Henri Mondor  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Magy","sequence":"additional","affiliation":[{"name":"Department of Neurology CHU de Limoges, H\u00f4pital Dupuytren  Limoges France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Philippe","family":"Camdessanch\u00e9","sequence":"additional","affiliation":[{"name":"Department of Neurology CHU de Saint\u2010\u00c9tienne, H\u00f4pital Nord  Saint\u2010\u00c9tienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Doghri","sequence":"additional","affiliation":[{"name":"Department of Neurology CHU de Tours, H\u00f4pital Bretonneau, CRC SEP  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Moulin","sequence":"additional","affiliation":[{"name":"Department of Neurology CHU de Reims, CRC\u2010SEP  Reims Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Sarov","family":"Rivi\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Neurology APHP, H\u00f4pital Kremlin Bic\u00eatre  Le Kremlin Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Hankiewicz","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital Pierre Delafontaine, Centre Hospitalier de Saint\u2010Denis  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-3873","authenticated-orcid":false,"given":"Am\u00e9lie Dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Neurology et Centre d'Investigation Clinique CIC INSERM 1402, CHU La Mil\u00e9trie, H\u00f4pital Jean Bernard  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Pottier","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital NOVO, Site Pontoise  Pontoise France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Manchon","sequence":"additional","affiliation":[{"name":"Department of Neurology CH de Gonesse  Gonesse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Aboab","sequence":"additional","affiliation":[{"name":"Centre Hospitalier National d'Ophtalmologie des Quinze\u2010Vingts  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Tchikviladze","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital Foch  Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0133-3274","authenticated-orcid":false,"given":"Thomas","family":"David","sequence":"additional","affiliation":[{"name":"Department of Neurology CHU de la Martinique  Fort\u2010de\u2010France France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Edan","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital of Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Le Page","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital of Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital of Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-3553","authenticated-orcid":false,"given":"Anne","family":"Kerbrat","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital of Rennes  Rennes France"},{"name":"Empenn U1228, University of Rennes, Inria, CNRS, Inserm, IRISA UMR  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"OFSEP Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"3","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab Versus Interferon Beta\u20101a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser S. L.","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab Efficacy in Subgroups of Patients With Relapsing Multiple Sclerosis","volume":"266","author":"Turner B.","year":"2019","journal-title":"Journal of Neurology"},{"issue":"12","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in Multiple Sclerosis Are Age\u2010 and Time\u2010Dependent","volume":"79","author":"Tremlett H.","year":"2008","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"12","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1177\/1352458519866613","article-title":"Age\u2010Related Decreases in Relapses Among Adults With Relapsing\u2010Onset Multiple Sclerosis","volume":"26","author":"Schwehr N. A.","year":"2020","journal-title":"Multiple Sclerosis"},{"issue":"8","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1177\/1352458519848090","article-title":"Decreasing Impact of Late Relapses on Disability Worsening in Secondary Progressive Multiple Sclerosis","volume":"26","author":"Ahrweiller K.","year":"2020","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","article-title":"Ageing and Multiple Sclerosis","volume":"22","author":"Graves J. S.","year":"2023","journal-title":"Lancet Neurology"},{"issue":"8","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: The Role of Aging in the Predisposition to Neuro\u2010Infectious Complications Arising From the Treatment of Multiple Sclerosis","volume":"17","author":"Grebenciucova E.","year":"2017","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"9","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1177\/1352458520964778","article-title":"Age\u2010Related Adverse Events of Disease\u2010Modifying Treatments for Multiple Sclerosis: A Meta\u2010Regression","volume":"27","author":"Prosperini L.","year":"2021","journal-title":"Multiple Sclerosis"},{"issue":"12","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1007\/s00415-020-10029-9","article-title":"Discontinuation of Disease\u2010Modifying Treatments for Multiple Sclerosis in Patients Aged Over 50 With Disease Inactivity","volume":"267","author":"Kaminsky A.\u2010L.","year":"2020","journal-title":"Journal of Neurology"},{"issue":"1","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00415-022-11341-2","article-title":"Discontinuation of Second\u2010 Versus First\u2010Line Disease\u2010Modifying Treatment in Middle\u2010Aged Patients With Multiple Sclerosis","volume":"270","author":"Chappuis M.","year":"2023","journal-title":"Journal of Neurology"},{"issue":"9","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/1352458516675751","article-title":"Discontinuation of Disease\u2010Modifying Therapies in Multiple Sclerosis \u2010 Clinical Outcome and Prognostic Factors","volume":"23","author":"Bsteh G.","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"10","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing Disease\u2010Modifying Therapy in MS After a Prolonged Relapse\u2010Free Period: A Propensity Score\u2010Matched Study","volume":"87","author":"Kister I.","year":"2016","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of Disease\u2010Modifying Therapy in Patients With Multiple Sclerosis Over Age 60","volume":"25","author":"Hua L. H.","year":"2019","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ene.13181","article-title":"Can We Stop Immunomodulatory Treatments in Secondary Progressive Multiple Sclerosis?","volume":"24","author":"Bonenfant J.","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"7","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of New Disease Activity in Patients With Multiple Sclerosis Who Continue or Discontinue Disease\u2010Modifying Therapies (DISCOMS): A Multicentre, Randomised, Single\u2010Blind, Phase 4, Non\u2010Inferiority Trial","volume":"22","author":"Corboy J. R.","year":"2023","journal-title":"Lancet Neurology"},{"issue":"5","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High\u2010Efficacy Therapy Discontinuation vs Continuation in Patients 50\u2009Years and Older With Nonactive MS","volume":"81","author":"Jouvenot G.","year":"2024","journal-title":"JAMA Neurology"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200152"},{"issue":"2","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","article-title":"Reduced Inflammation in Relapsing\u2010Remitting Multiple Sclerosis After Therapy Switch to Rituximab","volume":"87","author":"Flon P.","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained Low Relapse Rate With Highly Variable B\u2010Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis","volume":"10","author":"Starvaggi Cucuzza C.","year":"2023","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"7","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B\u2010Cell Tailored Dosing of Ocrelizumab in Patients With Multiple Sclerosis During the COVID\u201019 Pandemic","volume":"28","author":"Lierop Z. Y.","year":"2022","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1352458518815602","article-title":"Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP): A Unique Multimodal Nationwide MS Registry in France","volume":"26","author":"Vukusic S.","year":"2020","journal-title":"Multiple Sclerosis"},{"issue":"8","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.55.8.671","article-title":"EDMUS, a European Database for Multiple Sclerosis","volume":"55","author":"Confavreux C.","year":"1992","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"2","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria","volume":"17","author":"Thompson A. J.","year":"2018","journal-title":"Lancet Neurology"},{"issue":"8","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1352458517713668","article-title":"Comparative Effectiveness of Rituximab Relative to IFN\u2010\u03b2 or Glatiramer Acetate in Relapsing\u2010Remitting MS From the Swedish MS Registry","volume":"24","author":"Spelman T.","year":"2018","journal-title":"Multiple Sclerosis"},{"issue":"7","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/1352458517709619","article-title":"Greater Sensitivity to Multiple Sclerosis Disability Worsening and Progression Events Using a Roving Versus a Fixed Reference Value in a Prospective Cohort Study","volume":"24","author":"Kappos L.","year":"2018","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1541-0420.2005.00356.x","article-title":"Propensity Score Matching With Time\u2010Dependent Covariates","volume":"61","author":"Lu B.","year":"2005","journal-title":"Biometrics"},{"issue":"12","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/pds.5154","article-title":"Long\u2010Term Effect of First\u2010Line Injectable Multiple Sclerosis Treatments: Input of a Time\u2010Dependent Propensity Score","volume":"29","author":"Lefort M.","year":"2020","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"3","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213744","article-title":"Use of Disease\u2010Modifying Therapies in Patients With Late\u2010Onset Multiple Sclerosis","volume":"105","author":"Robin C.","year":"2025","journal-title":"Neurology"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The Ocrelizumab Phase II Extension Trial Suggests the Potential to Improve the Risk: Benefit Balance in Multiple Sclerosis","volume":"44","author":"Baker D.","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101468","article-title":"Interrupting Rituximab Treatment in Relapsing\u2010Remitting Multiple Sclerosis; no Evidence of Rebound Disease Activity","volume":"37","author":"Juto A.","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"6","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","article-title":"Discontinuation and Dose Reduction of Rituximab in Relapsing\u2013Remitting Multiple Sclerosis","volume":"268","author":"Boremalm M.","year":"2021","journal-title":"Journal of Neurology"},{"issue":"105900","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105900","article-title":"The Recurrence of Disease Activity After Ocrelizumab Discontinuation in Multiple Sclerosis","volume":"91","author":"Coerver E.","year":"2024","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"11","key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/13524585251375350","article-title":"Finite\u2010Course Ocrelizumab in Relapsing Multiple Sclerosis: Results of Two Prospective Open\u2010Label Trials With Matched Controls","volume":"31","author":"Salazar\u2010Camelo A.","year":"2025","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","article-title":"Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence From an Italian Multicenter Experience During the COVID\u201019 Pandemic","volume":"19","author":"Zangh\u00ec A.","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"5","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID\u201019","volume":"8","author":"Rolfes L.","year":"2021","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"2","key":"e_1_2_12_37_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214473","article-title":"Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis","volume":"106","author":"Langer\u2010Gould A.","year":"2026","journal-title":"Neurology"},{"issue":"8","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jamaneurol.2024.1961","article-title":"Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis","volume":"81","author":"Gavoille A.","year":"2024","journal-title":"JAMA Neurology"},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104706","article-title":"Discontinuation of First\u2010Line Disease\u2010Modifying Therapy in Relapse Onset Multiple Sclerosis","volume":"74","author":"Coerver E. M. E.","year":"2023","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna G.","year":"2020","journal-title":"JAMA Neurology"},{"issue":"8","key":"e_1_2_12_41_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209886","article-title":"Anti\u2010CD20 Therapies in Drug\u2010Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real\u2010Life Study","volume":"103","author":"Hay M.","year":"2024","journal-title":"Neurology"},{"issue":"3","key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ana.27281","article-title":"Effect of Cumulative Exposure to Ocrelizumab on Memory B\u2010Cell Repopulation Dynamics in Multiple Sclerosis","volume":"98","author":"Disanto G.","year":"2025","journal-title":"Annals of Neurology"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.70497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:58:14Z","timestamp":1786679894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":41,"alternative-id":["10.1002\/acn3.70497"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70497","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"2026-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"acn3.70497"}}